NCT02933502

Brief Summary

An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Jul 2016

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 11, 2016

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 11, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 14, 2016

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2017

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 2, 2018

Completed
11 months until next milestone

Results Posted

Study results publicly available

December 10, 2018

Completed
Last Updated

December 10, 2018

Status Verified

December 1, 2018

Enrollment Period

1.2 years

First QC Date

October 11, 2016

Results QC Date

November 12, 2018

Last Update Submit

December 5, 2018

Conditions

Scalp Psoriasis

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With HPA Axis Suppression

    Hypothalamic Pituitary Adrenal (HPA) Axis Response to stimulation

    day 28

Study Arms (1)

DSXS topical product

EXPERIMENTAL

treatment with DSXS once daily for 28 days

Drug: DSXS topical product

Interventions

DSXS topical productDRUG

treatment daily for 28 days

Also known as: Active
DSXS topical product

Eligibility Criteria

Age12 Years - 17 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Male or non-pregnant, non-lactating females 12-17 years of age.

You may not qualify if:

  • Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of child-bearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taro Pharmaceuticals USA Inc.

Hawthorne, New York, 10532, United States

Location

MeSH Terms

Interventions

Exercise

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Results Point of Contact

Title
Natalie Yantovskiy
Organization
Taro Pharmaceuticals U.S.A. Inc
Natalie.Yantovskiy@Taro.com
+1 914-345-9001

Study Officials

  • Novum Pharmaceutical Research Services

    http://www.novumprs.com/contact

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 11, 2016

First Posted

October 14, 2016

Study Start

July 11, 2016

Primary Completion

September 20, 2017

Study Completion

January 2, 2018

Last Updated

December 10, 2018

Results First Posted

December 10, 2018

Record last verified: 2018-12

Data Sharing

IPD Sharing
Will not share

Locations

US(1)